Clinical trials: Hodgkins Lymphoma
Large B Cell Lymphoma
Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
This randomized phase III trial studies rituximab when given together with two different combination chemotherapy regimens to compare how well they work in treating patients with diffuse large B-cell non-Hodgkin's lymphoma.
- Trial name
- NCT00118209
- Testing
- rituximab, cyclophosphamide, doxorubicin
- Where
- 47 sites in United States
- Volunteers
- 524 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Lymphoma
Lenalidomide and Rituximab in the Treatment of Relapsed Mantle Cell Lymphoma (MCL) and Diffuse Large B-Cell Lymphoma
The goal of this clinical research study is to find the highest tolerable dose of the drug lenalidomide (Revlimid, lenalidomide) that can be given with Rituxan® (rituximab) in the treatment of relapsed mantle cell lymphoma.
- Trial name
- NCT00294632
- Testing
- Lenalidomide, Rituximab
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- M.D. Anderson Cancer Center
Lymphoma, Malignant, Hodgkin's Lymphoma
A Phase 1 Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies
This is a Phase 1 dose escalation study to determine the maximum tolerated dose and the dose limiting toxicities of SB1518 when given alone once daily by mouth to subjects with advanced lymphoid malignancies.
- Conditions
- Lymphoma, Malignant, Hodgkin's Lymphoma, B Cell Lymphoma
- Trial name
- NCT00741871
- Testing
- SB1518
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- S*BIO
Leukemia, Lymphoma
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of suberoylanilide hydroxamic acid in treating patients who…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Prostate Cancer
- Trial name
- NCT00005634
- Testing
- vorinostat
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hodgkin's Disease
A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant,
The purpose of this study is to determine whether an investigational immuno-therapy combination, nivolumab with Brentuximab vedotin compared to Brentuximab vedotin alone is safe and effective in the treatment of relapsed and…
- Trial name
- CheckMate 812 (NCT03138499)
- Testing
- Nivolumab, Brentuximab vedotin
- Where
- 22 sites in United States, Japan and 1 more
- Volunteers
- 23 people
- Sponsor
- Bristol-Myers Squibb
Hodgkin Lymphoma
Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Hodgkin Lymphoma.
This study aims to evaluate the efficacy of brentuximab vedotin + AVD combination (doxorubicine, vinblastine, dacarbazine) in patients with Hodgkin lymphoma stage I / II with an unfavorable diagnosis, assessed by the negativity…
- Trial name
- BREACH (NCT02292979)
- Testing
- Doxorubicin, Bleomycin, Vinblastine
- Where
- 65 sites in Belgium, Croatia and 3 more
- Volunteers
- 170 people
- Sponsor
- The Lymphoma Academic Research Organisation
Non Hodgkin Lymphoma
Antineoplaston Therapy in Treating Patients With Non-Hodgkin's Lymphoma
Current therapies for Non-Hodgkin's Lymphoma provide limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of Non-Hodgkin's Lymphoma.
- Trial name
- NCT00003498
- Testing
- Antineoplaston therapy (Atengenal + Astugenal)
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Burzynski Research Institute
Multiple Myeloma, Non-Hodgkins Lymphoma
Study of Plerixafor for Rescue of Poor Mobilizers in Autologous Stem Cell Transplant
Plerixafor, administered at a dose of 240 ug/kg, potentiates the effect of granulocyte colony-stimulating factor (G-CSF) to increase peripheral blood progenitor cells in both healthy volunteers and cancer patients.
- Conditions
- Multiple Myeloma, Non-Hodgkins Lymphoma, Hodgkins Disease
- Trial name
- NCT00901225
- Testing
- G-CSF plus Plerixafor
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Duke University
Non Hodgkin Lymphoma
Chidamide in Combination With Decitabine in Non-Hodgkin's Lymphoma Relapsed After Chimeric Antigen Receptor
This is a Phase I/II clinical trial for patients with r/r Non-Hodgkin's Lymphoma relapsed after chimeric antigen receptor T cells infusion.
- Trial name
- NCT04337606
- Testing
- Chidamide, Decitabine, Camrelizumab
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Chinese PLA General Hospital
Multiple Myeloma, Non-Hodgkin Lymphoma
Preservation of Ovarian Function After Hematopoietic Cell Transplant
Women undergoing myeloablative allogeneic hematopoietic cell transplant (MA HCT) will receive GnRH agonist leuprolide. Women undergoing reduced intensity allogeneic (RIC) HCT will be observed.
- Conditions
- Multiple Myeloma, Non-Hodgkin Lymphoma, Hodgkin Disease, Acute Myeloid Leukemia
- Trial name
- NCT01343368
- Testing
- Leuprolide, hematopoietic cell transplant, reduced intensity allogeneic HCT
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
CD30-Positive Diffuse Large B-Cell Lymphoma, Anaplastic Large Cell Lymphoma, T Cell and Null Cell Type
Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
This study involves patients with diffuse large B cell lymphoma (DLBCL), natural killer/T-cell lymphoma (NKTL), or classical Hodgkin lymphoma (cHL) (referred to collectively as lymphoma) whose disease has returned or not…
- Conditions
- CD30-Positive Diffuse Large B-Cell Lymphoma, Anaplastic Large Cell Lymphoma, T Cell and Null Cell Type, Anaplastic Large Cell Lymphoma, ALK-Positive, Peripheral T-cell Lymphoma
- Trial name
- CABAL2 (NCT06176690)
- Testing
- C7R.CD30.CAR-EBVST cells
- Where
- 2 sites in United States
- Volunteers
- 90 people
- Sponsor
- Baylor College of Medicine
Non-hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma
Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma
The goal of this clinical trial is to reduce the duration of ICANS and incidence of G3 or great ICANS in participants who receive axi-cel.
- Conditions
- Non-hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
- Trial name
- NCT07763210
- Testing
- Therapeutic Hydrocortisone, Cytarabine, Dexamethasone
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Lymphoma
Bleomycin in Treating Patients With Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of bleomycin in treating patients with non-Hodgkin's…
- Trial name
- NCT00003110
- Testing
- bleomycin sulfate
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Case Comprehensive Cancer Center
Lymphoma, Primary Effusion
Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease
Background: Primary effusion lymphoma (PEL), plasmablastic lymphoma (PBL), and Multicentric Castleman Disease (MCD) are aggressive forms of cancer that affects cells in the immune system and lymph nodes.
- Trial name
- NCT05907759
- Testing
- Daratumumab SC
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Hodgkins Lymphoma
Allogeneic Stem Cell Transplantation With Adoptive Immunotherapy in Epstein-Barr Virus Positive Recurrent/Refractory Hodgkins Lymphoma
The investigators intend to utilize reduced intensity conditioning and allogeneic stem cell transplant from EBV positive HLA matched sibling or unrelated adult donor combined with post AlloSCT allogeneic donor derived LMP…
- Trial name
- NCT01636388
- Testing
- allogeneic donor derived LMP specific cytotoxic T-lymphocyte
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- New York Medical College
Hodgkin Lymphoma
Comparison of AVD + Low-Dose Nivolumab vs. PET-Adapted BEACOPP-like in Advanced cHL
Patients in this prospective multicenter phase II study will be randomized between two first-line therapy strategies for advanced stages of cHL.
- Trial name
- NCT07234487
- Testing
- Nivo-AVD, BEACOPP-like
- Where
- 3 sites in Russia
- Volunteers
- 178 people
- Sponsor
- St. Petersburg State Pavlov Medical University
Classical Hodgkin Lymphoma
Consolidation Therapy With Brentuximab Vedotin After Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma
The aim of the trial is to improve disease control after an allogeneic stem cell transplantation (alloSCT) for relapsed or refractory classical Hodgkin lymphoma (rrHL, cHL) with consolidation therapy by Brentuximab Vedotin (BV)…
- Trial name
- NCT03652441
- Testing
- Brentuximab Vedotin
- Where
- Germany
- Volunteers
- 14 people
- Sponsor
- University of Cologne
Melanoma Stage III, B-cell Non Hodgkin Lymphoma
Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies
The goal of this Long-Term Follow-Up Trial is to assess long-term safety and efficacy of Miltenyi CAR T treatment.
- Conditions
- Melanoma Stage III, B-cell Non Hodgkin Lymphoma, Pediatric ALL, Childhood Non-Hodgkin Lymphoma
- Trial name
- LONGSAFE (NCT06508775)
- Testing
- MB-CART19.1, MB-CART20.1, MB-CART2019.1
- Where
- 7 sites in Germany
- Volunteers
- 40 people
- Sponsor
- Miltenyi Biomedicine GmbH
Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia
A Study of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia And DCDT2980S in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non Hodgkin's Lymphoma
This is a Phase I, multicenter, open-label, dose-escalation study of DCDT2980S administered by intravenous (IV) infusion to patients with relapsed or refractory hematologic malignancies.
- Trial name
- NCT01209130
- Testing
- DCDT2980S, rituximab
- Where
- 9 sites in United States
- Volunteers
- 91 people
- Sponsor
- Genentech, Inc.
Lymphoma, Non-Hodgkin's
A Study of Galiximab + Rituximab Versus Rituximab + Placebo in Follicular Non-Hodgkin's Lymphoma (NHL)
This is a Phase III, multicenter, global, clinical study of an investigational drug called galiximab in combination with an approved drug called rituximab in subjects with follicular NHL.
- Trial name
- NCT00363636
- Testing
- Galiximab in combination with rituximab
- Volunteers
- 340 people
- Sponsor
- Biogen